Economic evaluation of vaccines in Canada: A systematic review

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 5, 2016, Pages 1257-1264

  Chit, Ayman ^a,b   Lee, Jason K H ^a,b   Shim, Minsup ^b   Nguyen, Van Hai ^c   Grootendorst, Paul ^b,d   Wu, Jianhong ^e   Van Exan, Robert ^a   Langley, Joanne M ^f  

^a Sanofi Pasteur   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d MCMASTER UNIVERSITY   (Canada)

^e YORK UNIVERSITY   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Canada; cost effectiveness; economics; review; vaccine

Indexed keywords

VACCINE;

ARTICLE; CANADA; CHICKENPOX; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; INFLUENZA; MEASLES; MENINGOCOCCOSIS; PERTUSSIS; PNEUMOCOCCAL INFECTION; ROTAVIRUS; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; BRITISH COLUMBIA; DECISION MAKING; ECONOMICS; HUMAN; ONTARIO; OUTCOME ASSESSMENT; PREVENTIVE HEALTH SERVICE; QUEBEC; VACCINATION;

BRITISH COLUMBIA; CANADA; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; IMMUNIZATION PROGRAMS; ONTARIO; OUTCOME ASSESSMENT (HEALTH CARE); QUEBEC; VACCINATION; VACCINES;

EID: 84964506427     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1137405     Document Type: Article

References (53)

1. BIOTECanada Vaccine Industry Committee. Building on the Legacy of Vaccines in Canada: Value, Opportunities, and Challenges Series: Paper 2 – The Current Canadian Vaccine Environment. 2010
2. J.Kim The role of cost-effectiveness in US vaccination policy. N Engl J Med. 2011 Nov 10; 365(19):1760-1; http://dx.doi.org/10.1056/NEJMp1110539
3. P.Duclos. National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening. Vaccine 2010; 28(Suppl 1):A18-25; PMID:20412991; http://dx.doi.org/10.1016/j.vaccine.2010.02.027
4. J.Giesecke. Modern infectious disease epidemiology. Second edition. London: Arnold, a member of the Hodder Headline group, 2002
5. J.C.Smith. The structure, role, and procedures of the US. Advisory Committee on Immunization Practices (ACIP). Vaccine 2010; 28(Suppl 1):A68-75; PMID:20413002; http://dx.doi.org/10.1016/j.vaccine.2010.02.037
6. A.J.Hall. The United Kingdom Joint Committee on Vaccination and Immunisation. Vaccine 2010; 28(Suppl 1):A54-7; PMID:20412998; http://dx.doi.org/10.1016/j.vaccine.2010.02.034
7. T.M.Nolan. The Australian model of immunization advice and vaccine funding. Vaccine 2010; 28(Suppl 1):A76-83; PMID:20413003; http://dx.doi.org/10.1016/j.vaccine.2010.02.038
8. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies. CADTH; Ottawa:Canada: 2006
9. J.M.Langley, M.Krahn, D.Husereau, J.Spika, D.N.Fisman, A.Chit, R.Van Exan. Incorporating economic evaluation into immunization decision making in Canada: a workshop. Expert Rev Vaccines 2014 Nov; 13(11):1291-6; http://dx.doi.org/10.1586/14760584.2014.939637
10. M.C.Weinstein, B.O'Brien, J.Hornberger, J.Jackson, M.Johannesson, C.McCabe, B.R.Luce. Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 2003; 6(1):9-17; PMID:12535234; http://dx.doi.org/10.1046/j.1524-4733.2003.00234.x
11. M.L.Berger, M.Mamdani, D.Atikns, M.L.Johnson. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonradomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report – Part I. Value Health. 2009; 12(8):1044-52; PMID:19793072; http://dx.doi.org/10.1111/j.1524-4733.2009.00600.x
12. E.Cox, B.C.Martin, T.Van Staa, E.Garbe, U.Siebert, M.L.Johnson. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effect using secondary data sources: the International Society of Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report - Part II. Value Health 2009; 12(8):1053-61; PMID:19744292; http://dx.doi.org/10.1111/j.1524-4733.2009.00601.x
13. M.L.Johnson, W.Crown, B.C.Martin, C.R.Dormuth, U.Siebert. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III. Value Health 2009; 12(8):1062-73; PMID:19793071; http://dx.doi.org/10.1111/j.1524-4733.2009.00602.x
14. R.Pitman, D.Fisman, G.S.Zaric, M.Postma, M.Kretzschmar, J.Edmunds, M.Brisson. Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. Value Health 2012; 15:828-34; PMID:22999132; http://dx.doi.org/10.1016/j.jval.2012.06.011
15. A.Briggs, M.C.Weinstein, E.A.L.Fenwick, J.Karnon, M.J.Sculpher, D.Paltiel. Model parameter estimation and uncertainty analysis: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group. J Med Decis Making 2012; 32:722-32
16. M.Drumond, R.Brown, M.A.Fendrick, P.Fullerton, P.Neumann, R.Taylor, M.Barbieri. Use of pharmacoeconomics information—Report of the ISPOR task force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003; 6(4):407-16; PMID:12859580; http://dx.doi.org/10.1046/j.1524-4733.2003.64245.x
17. M.Drumond, M.Barbieri, J.Cook, H.Glick, J.Lis, F.Malik, S.D.Reed, F.Rutten, M.Sculpher, J.Severens. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009; 12(4):409-18; PMID:19900249; http://dx.doi.org/10.1111/j.1524-4733.2008.00489.x
18. J.W.Hay, J.Smeeding, N.V.Carroll, M.Drummond, L.Garrision, E.C.Mansely, C.D.Mullins, J.M.Mycka, B.Seal, L.Shi. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: The ISPOR drug cost task force report—Part I. Value Health 2010; 13(1):3-7; PMID:19874571; http://dx.doi.org/10.1111/j.1524-4733.2009.00663.x
19. L.Garrison, E.C.Mansley, T.A.Abbot, B.Bresnahan, J.W.Hay, J.Smeeding. Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses:A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II. Value in Health 2010; 13(1):8-13vvhe_663 3.7; PMID:19883405; http://dx.doi.org/10.1111/j.1524-4733.2009.00660.x
20. University of Connecticut guide to using the Likert scale. http://www.gifted.uconn.edu/siegle/research/instrument%20reliability%20and%20validity/likert.html. Accessed: 2December2013
21. A.Laupacis, D.Feeny, A.S.Detsky, P.X.Tugwell. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146(4):473-81; PMID:1306034
22. World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). World Health Organization 2014. Available at: http://www.who.int/choice/costs/CER_thresholds/en/. Accessed 5June2014
23. World Bank. GDP per capita (current US$). World Development Indicators. Washington, DC, USA. Available at: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 5June2014
24. S.J.Ismail, J.M.Langley, T.M.Harris, B.F.Warshawsky, S.Desai, M.FarhangMehr. Canada's National Advisory Committee on Immunization (NACI): evidence-based decision-making on vaccines and immunization. Vaccine 2010; 28:A58-63; PMID:20412999; http://dx.doi.org/10.1016/j.vaccine.2010.02.035
25. P.De Wals, L.Erickson. Economic analysis of the 1992–1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine 2002; 20(21):2840-4; PMID:12102036; http://dx.doi.org/10.1016/S0264-410X(02)00161-5
26. P.De Wals, L.J.Erickson, M.Guay, J.Drapeau, J.St-Laurent. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004; 22(9):1233-40; PMID:15003652; http://dx.doi.org/10.1016/j.vaccine.2003.09.022
27. M.D.Krahn, A.John-Baptiste, Q.Yi, A.Doria, R.S.Remis, P.Ritvo, S.Friedman. Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine 2005; 23(13):1549-58; PMID:15694507; http://dx.doi.org/10.1016/j.vaccine.2004.09.023
28. C.T.Bauch, A.M.Anonychuk, B.Z.Pham, V.Gilca, B.Duval, M.D.Krahn. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007; 25(51):8536-48; PMID:17996339; http://dx.doi.org/10.1016/j.vaccine.2007.10.001
29. M.Brisson, N.Van de Velde, P.De Wals, M.C.Boily. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25(29):5399-408; PMID:17561316; http://dx.doi.org/10.1016/j.vaccine.2007.04.086
30. P.De Wals, L.Coudeville, P.Trottier, C.Chevat, L.J.Erickson. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine 2007; 25(29):5433-40; PMID:17560695; http://dx.doi.org/10.1016/j.vaccine.2007.04.071
31. M.Brisson, J.M.Pellissier, S.Camden, C.Quach, P.De Wals. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Human Vaccines 2008; 4(3):238-45; PMID:18382137; http://dx.doi.org/10.4161/hv.4.3.5686
32. D.Debicki, N.Ferko, N.Demarteau, S.Gallivan, C.Bauch, A.Anonychuk, L.Annemans. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 2008; 26:F16-28; PMID:18992379; http://dx.doi.org/10.1016/j.vaccine.2008.02.040
33. M.Najafzadeh, C.A.Marra, E.Galanis, D.M.Patrick. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 2009; 27(12):991-1004; PMID:19908924; http://dx.doi.org/10.2165/11314010-000000000-00000
34. A.M.Anonychuk, C.T.Bauch, M.F.Merid, G.Van Kriekinge, N.Demarteau. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009; 9(1):401; PMID:19878578; http://dx.doi.org/10.1186/1471-2458-9-401
35. B.Poirier, P.De Wals, G.Petit, L.J.Erickson, & J.Pépin. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2009; 27(50):7105-09; PMID:19786137; http://dx.doi.org/10.1016/j.vaccine.2009.09.057
36. B.Sander, C.T.Bauch, D.Fisman, R.A.Fowler, J.C.Kwong, A.Maetzel, M.Krahn. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. Vaccine 2010; 28(38):6210-20; PMID:20643091; http://dx.doi.org/10.1016/j.vaccine.2010.07.010
37. B.Sander, J.C.Kwong, C.T.Bauch, A.Maetzel, A.McGeer, J.M.Raboud, M.Krahn. Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med 2010; 7(4):e1000256; PMID:20386727; http://dx.doi.org/10.1371/journal.pmed.1000256
38. A.W.Chuck, P.Jacobs, G.Tyrrell, J.D.Kellner. Pharmacoeconomic evaluation of 10-and 13-valent pneumococcal conjugate vaccines. Vaccine 2010; 28(33):5485-90; PMID:20554066; http://dx.doi.org/10.1016/j.vaccine.2010.05.058
39. W.W.Wong, G.Woo, E.Jenny Heathcote, M.Krahn. Cost effectiveness of screening immigrants for hepatitis B. Liver Int 2011; 31(8):1179-90; PMID:21745300; http://dx.doi.org/10.1111/j.1478-3231.2011.02559.x
40. S.P.Tully, A.M.Anonychuk, D.M.Sanchez, A.P.Galvani, C.T.Bauch. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine 2012; 30(2):425-35; PMID:22075091; http://dx.doi.org/10.1016/j.vaccine.2011.10.067
41. D.N.Fisman, A.R.Tuite. Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. PloS One 2011; 6(11):e27420; PMID:22110645; http://dx.doi.org/10.1371/journal.pone.0027420
42. B.Nosyk, B.Sharif, H.Sun, C.Cooper, A.H.Anis, CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus 2011
43. A.L.Greer, D.N.Fisman. Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers. Pediatrics 2011; 128(3):e591-9; PMID:21844056
44. M.Kohli, D.Lawrence, J.Haig, A.Anonychuk, N.Demarteau. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada. BMC Public Health 2012; 12(1):872; PMID:23061913; http://dx.doi.org/10.1186/1471-2458-12-872
45. D.N.Fisman, C.H.Chan, E.Lowcock, M.Naus, V.Lee. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: A model-based evaluation. Vaccine 2012; 30(52):7601-7; PMID:23107595; http://dx.doi.org/10.1016/j.vaccine.2012.10.034
46. D.Coyle, K.Coyle, J.A.Bettinger, S.A.Halperin, W.Vaudry, D.W.Scheifele, N.Le Saux. Cost effectiveness of infant vaccination for rotavirus in Canada. Canadian J Infect Dis Medical Microbiol 2012; 23(2):71; PMID:23730312
47. P.J.Neumann, P.W.Stone, R.H.Chapman, E.A.Sandberg, C.M.Bell. The quality of reporting in published cost-utility analyses, 1976–1997. Annals Internal Med 2000; 132(12):964-72; PMID:10858180; http://dx.doi.org/10.7326/0003-4819-132-12-200006200-00007
48. P.W.Stone, E.Larson, L.N.Kawar. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Control 2002; 30(3):145-52; PMID:11988708; http://dx.doi.org/10.1067/mic.2002.121099
49. M.C.Weinstein, G.Torrance, A.McGuire. QALYs: The Basics. Value Health 2009; 12(1):S5-9; PMID:19250132; http://dx.doi.org/10.1111/j.1524-4733.2009.00515.x
50. National Advisory Committee on Immunization. Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations. Can Commun Dis Rep 2009; 36(ACS-3):1-40
51. National Advisory Committee on Immunization. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI): Update on the use of herpes zoster vaccine. Public Health Agency Canada January 2014 (Catalogue no. HP40-92/2014E-PDF)
52. National Advisory Committee on Immunization. Updated statement of the use of rotavirus vaccines. Can Commun Dis Rep 2010:36(ACS-4):1-37
53. M.Barbieri, M.F.Drummond. Conflict of interest in industry-sponsored economic evaluations: Real or imagined? Curr Oncol Reports 2001; 3(5):410-13; PMID:11489241; http://dx.doi.org/10.1007/s11912-001-0027-2